Browse

Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases.

RIO DE JANEIRO, Brazil — For the past two years, Adaptyv Bio has challenged the AI community to see how good today’s models are at designing proteins. Its latest competition, presented Monday at a…

Decades before CRISPR gene editing was invented, scientists tried to manipulate genes with enzymes called recombinases. The proteins were precise but proved tricky to use because they were hardwire…